Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based CD25-Targeting Antibody Drug Conjugate, in a Phase 1 Study of Relapsed/Refractory Non-Hodgkin Lymphoma Shows Activity in T-Cell Lymphoma
Conclusions: In pts with R/R NHL, active doses of Cami-T with acceptable safety profiles were identified for both B-cell and T-cell lymphoma during dose escalation of this study. Five out of the 10 pts on study with T-cell lymphoma treated in the 60, 80, or 100 µg/kg cohorts responded. Subtype-specific cohorts in the dose escalation portion of this study are underway to better define the recommended dose for expansion.Study sponsored by ADC Therapeutics. http://clinicaltrials.gov/show/NCT02432235.DisclosuresCollins: MSD: Consultancy, Honoraria; ADC Therapeutics: Consultancy, Honoraria, Research Funding; Roche: Consultancy, Honoraria, Speakers Bureau; Gilead: Consultancy, Honoraria, Speakers Bureau; Celleron: Consultancy, Honoraria; Takeda: Consultancy, Honoraria, Speakers Bureau; Amgen: Research Funding; BMS: Consultancy, Honoraria, Research Funding; Amgen: Research Funding; Pfizer: Consultancy, Honoraria; Celgene Corporation: Research Funding; ADC Therapeutics: Consultancy, Honoraria, Research Funding; Celgene Corporation: Research Funding. Horwitz: Seattle Genetics: Consultancy, Research Funding; ADC Therapeutics: Consultancy, Research Funding; Celgene: Consultancy, Research Funding; Aileron Therapeutics: Consultancy, Research Funding; Innate Pharma: Consultancy; Forty Seven: Consultancy, Research Funding; Millennium/Takeda: Consultancy, Research Funding; Corvus: Consultancy; Portola: Consultancy; Mundipharma: Consultancy; Kyowa-Hakka-Kirin: Consultancy, Research Fund...
Source: Blood - Category: Hematology Authors: Collins, G. P., Horwitz, S. M., Davies, A., Karnad, A., Samaniego, F., Spira, A. I., Fields, P. A., Menne, T., Boni, J., Cruz, H., Feingold, J., He, S., Wuerthner, J., Hamadani, M. Tags: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma-Clinical Studies: Poster I Source Type: research
More News: AstraZeneca | Burkitt Lymphoma | Clinical Trials | Cutaneous T cell lymphoma | Dermatitis | Dermatology | Employment | Genetics | Hyperthyroidism | Hypothyroidism | Leukemia | Lymphoma | Men | Merck | Mycosis Fungoides | Non-Hodgkin's Lymphoma | Pfizer | Pharmaceuticals | Stem Cell Therapy | Stem Cells | Study | T-cell Lymphoma | Thyroiditis | Transplant Surgery | Transplants